- Open Access
Possible immunotherapeutic potentiation with D-Fraction in prostate cancer cells
© Pyo et al; licensee BioMed Central Ltd. 2008
Received: 31 October 2008
Accepted: 04 December 2008
Published: 04 December 2008
Prostate cancer remains the most common malignancy among elderly men and the second leading cause of cancer death in the United States. Although several conventional therapies are currently available, they have a low efficacy and the more effective treatment modalities need to be established. Interferons (IFNs) are one of such options known as immunotherapy and demonstrated their antitumor effects on certain cancer types. Yet such antitumor activity should be improved or potentiated to have the satisfactory outcomes. In fact, combination therapy has been proposed as an alternative approach and is being underway in human and animal studies. Accordingly, we studied whether the combination of IFN-α and D-fraction (PDF), a bioactive mushroom extract, might potentiate anticancer activity of IFN-α in prostate cancer PC-3 cells in vitro.
Potential effects of recombinant IFN-α2b (0–100,000 IU/ml), PDF (0–1,000 μg/ml), or their combinations were assessed on the growth of PC-3 cells at 72 h. Cell cycle analysis using a flow cytometer and Western blot analysis were performed to explore antiproliferative mechanism of these agents. The dose-dependent study showed that IFN-α2b up to 20,000 (20 K) IU/ml had no significant effects, but >60% growth reduction was attained ≤50 K IU/ml. Similarly, PDF showed no effects up to 250 μg/ml but ~65% growth reduction was seen at 1,000 μg/ml. When IFN-α2b and PDF were combined, a relatively low concentration (10 K IU/ml) of IFN-α2b and PDF (250 μg/ml) resulted in a ~65% growth reduction. This was accompanied by a G1 cell cycle arrest, indicated by cell cycle analysis. Western blots also revealed that the G1-specific cell cycle regulators, CDK2, CDK4, CDK6, cyclin D1, and cyclin E, had been significantly (>60%) down-regulated in IFN/PDF-treated cells.
The combination of IFN-α2b (10 K IU/ml) and PDF (250 μg/ml) is capable of inducing a ~65% reduction in PC-3 cell growth. This appears to be due to a synergistic potentiation of two agents, leading to a G1 cell cycle arrest. Thus, it is conceivable that PDF may potentiate IFN-α2b activity, improving immunotherapy for prostate cancer.
Current therapy for prostate cancer (CaP), the most common malignancy in elderly men in the United States , is directed at exploitation of the androgen-dependent state of prostatic cancer cells. Various antiandrogens and leuteinizing hormone-releasing hormone (LHRH) agonists are useful for blocking the availability of androgen to the cancer cells . However, the efficacy of these drugs is of limited duration, and patients experience an almost inevitable progression of their cancers to the fatal androgen-independent state . To develop an alternative approach for controlling or preventing such disease progression, it demands in searching for agents/drugs that could effectively regulate the CaP proliferation.
Interferons (IFNs) are known to trigger multiple cellular responses including antiviral activity, growth inhibition, cell differentiation and immunoregulation . Many studies have also focused on the potential antitumor effects of IFNs using both in vitro and in vivo cancer models . For instance, IFNs have been widely used as immunotherapy for urological malignancies including prostate, bladder, and renal carcinomas [6–8]. Compared to chemotherapy, less or moderate side effects of IFNs have also been shown to be beneficial to cancer patients. Some encouraging data from such IFN monotherapy have been reported , although they are yet somewhat inconsistent and conflicting. In addition, particularly in clinical CaP cases, IFN therapy has several drawbacks such as high cost and repeated administration . These disadvantages thus limit its use in clinical practice, and further exploration of improved treatment modality, e.g. combination therapy, is required.
The D-fraction (PDF), the unique proteoglucan extracted from maitake mushroom (Grifola frondosa), is the acid-insoluble, alkali-soluble and hot water-extractable fraction . It structurally consists of either β-1,6-linked glucan with β-1,3 branches or β-1,3 glucan branched with β-1,6 glucosides, having a molecular weight of ~1 × 106 dalton . PDF has been commercially available for a variety of medical and scientific research, and a number of published and unpublished studies have thus far suggested the immunomodulatory and antitumor activities of PDF [11–13]. It has been shown in an animal model that PDF was capable of activating immune-competent cells such as natural killer cells and cytotoxic T-cells with a concomitant increase in interleukin-1 production , indicating stimulation of immune responses. A preventive or inhibitory activity of PDF on carcinogenesis and metastasis has also been demonstrated in mice , suggesting its antitumor activity. Moreover, a chemosensitizing effect of PDF has been postulated on conventional anticancer drugs being currently used .
Accordingly, we are interested in investigating whether the combination of IFN-α2b and PDF may have the potentiated growth inhibitory effects on prostatic cancer cells in vitro. Such studies may provide us with useful information on the improved efficacy of IFN therapy on prostate cancer.
Effects of IFN-α2b or PDF on PC-3 cell growth
Synergistic growth inhibitory effects of IFN-α2b and PDF
Effects of IFN-α2b, PDF, or their combination on cell cycle
Down-regulation of cell cycle regulators by IFN-α2b/PDF combination
IFNs belong to the family of cytokines and are capable of activating a cascade of intracellular pathways that regulate cell growth/differentiation and also produce antiviral and immunological responses [4, 15]. Particularly, the antitumor potential of IFNs gained a great attention and has been extensively investigated for over two decades. Some early studies showed that IFNs had induced regression of tumors in a significant number of patients with metastatic breast cancer, low-grade lymphoma, and multiple myeloma . However, the efficacy of IFNs on tumor regression was also found to vary with cancer types , and some data from specific IFN monotherapy indeed showed such discrepancy. Moreover, a high cost and repetitive administration of IFN (monotherapy) somewhat limit its clinical utility. Accordingly, reducing a cost while improving the efficacy of IFNs, "combination" therapy has been proposed and promoted.
In the present study, we explored such combination therapy as an alternative approach for prostate cancer immunotherapy; i.e. combination of IFN-α2b and D-fraction (PDF). Dose-dependent studies showed that IFN-α2b ≥ 50 K IU/ml or PDF at 1,000 μg/ml was capable of inducing >60% growth reduction in prostate cancer PC-3 cells (Fig. 1). Moreover, a ~65% growth reduction was attained with the combination of 10 K IU/ml IFN-α2b and 250 μg/ml PDF (Fig. 2). This augmented growth inhibition results conceivably from a synergistic potentiation of two agents, because neither 10 K IU/ml IFN-α2b nor 250 μg/ml PDF alone has any growth inhibitory activity (Fig. 1). Thus, the relatively low concentrations of IFN-α2b and PDF when combined are required for their potentiated antiproliferative effects. In other words, to attain the same growth inhibitory effect (~65%) induced by 50 K IU/ml of IFN-α2b alone, merely "1/5th" (10 K IU/ml) of that IFN-α2b would be needed when combined with PDF. It is then plausible that PDF may not only help potentiate IFN-α2b activity but also help cut the cost down.
We next examined the effects of IFN-α2b/PDF combination on the cell cycle regulation in order to explore the growth inhibitory mechanism. Cell cycle analysis revealed a ~63% decrease in the S-phase cell number with a concomitant 55% increase in the G1-phase cell number following the treatment of IFN-α2b/PDF combination (Fig. 3). The resulting "G1 cell accumulation" is termed a G1 cell cycle arrest, accounting in part for the ultimate growth cessation. In addition, the expressions of specific G1 cell cycle regulators, such as CDK2, CDK4, CDK6, and cyclins D1/E, were all markedly (>60%) down-regulated (Fig. 4). Thus, these findings suggest that the growth inhibitory action of IFN-α2b/PDF combination may target primarily the G1-S phase transition in the cell cycle, resulting in a G1 arrest.
Yet, it should be also noted that IFNs are known to modulate many proteins and enzymes , particularly specific protein kinases acting on the signal transduction pathway for cell proliferation and/or differentiation. In other words, IFNs can regulate cell growth through the signal transduction mediated by these protein kinases. Additionally, it has been documented that IFNs could induce DNA fragmentation, leading to an accumulation of small or low-molecular-weight DNA . This may imply activation of a specific protein kinase called double-stranded DNA-dependent protein kinase (DNA-PK), which requires small double-stranded DNA for its activation . DNA-PK is also believed to play an important role in the cell cycle regulation . These information further suggest that our IFN-α2b/PDF combination may affect certain protein kinase(s), triggering the specific cascade events (via the signal transduction) on the cell cycle to ultimately cease cancer cell growth. Therefore, such biochemical studies are undoubtedly required and being underway in our laboratory.
In addition, it is important to further investigate whether the enhanced growth inhibitory effect of IFN-α2b/PDF combination observed in this in vitro study might be also demonstrated in animal study (in vivo). Such study would then allow us to assess the actual efficacy of IFN-α2b/PDF combination on prostate tumor grown in mice and to determine the effective or tolerable physiological concentrations of these agents. This will be conducted shortly as our Phase II study.
Furthermore, the safety of IFN-α2b or PDF in human use would be certainly concerned. IFN-α2b has been often used in immunotherapy for various cancer patients and its concentrations up to 5 × 106 IU have been shown to be relatively safe and tolerable in those with prostate cancer [9, 22]. It eventually needs to be determined how the effective concentration of 10 K IU/ml IFN-α2b (in combination with PDF) in this study would be extrapolated to actual patients. For PDF, early animal and clinical studies ascertained the safety of PDF without any side/adverse effects . This was further supported by the fact that the U.S. Food and Drug Administration (FDA) had exempted D-fraction from a Phase I toxicology study. The FDA has also approved PDF for an Investigational New Drug (IND) application to conduct a Phase II pilot study on patients with advanced breast and prostate cancer . Although such clinical trials are currently in progress, the effective concentrations of PDF yet remain to be established. Taken together, our next animal study is crucial and indisputably required for confirming the safety of IFN-α2b and PDF and also obtaining valid information on their effective and tolerable physiological concentrations. It may then help lead us to an ultimate clinical trial in the future.
In summary, the combination of IFN-α2b and PDF demonstrates a synergistic antiproliferative activity on prostate cancer PC-3 cells. This potentiated growth inhibition results primarily from a G1 cell cycle arrest. Therefore, the low-dose IFN-α2b/PDF combination may provide an alternative, improved immunotherapy for prostate cancer, implying its clinical utility/application. It is promising but further studies are yet required.
The human prostate cancer PC-3 cells, derived from a patient with bone metastasis, were obtained from the American Type Culture Collection (Rockville, MD). Cells were maintained in RPMI-1640 medium containing 10% fetal bovine serum, penicillin (100 U/ml), and streptomycin (100 μg/ml). Routinely, culture medium was changed every 3 to 4 days and the passage of cells was performed weekly. For experiments, cells were seeded in T-75 flasks or 6-well culture plates at the initial cell density of 1 × 105 cells/ml and were cultured with recombinant interferon-α2b (IFN-α2b; Schering Corp., Kenilworth, NJ), D-fraction (PDF; Maitake Products, Inc., Paramus, NJ) or their combinations. Cell numbers were then assessed at specified times using the trypan blue exclusion method.
Cell cycle analysis
A FACScan flow cytometer (Becton-Dickinson, San Jose, CA), equipped with a double discrimination module, was employed for cell cycle analysis. Approximately 1 × 106 cells were resuspended in 500 μl of propidium iodide solution (20 μg/ml propidium iodide, 0.2 mg/ml RNase, 0.2 mg/ml EDTA, 0.5% NP-40) and incubated at room temperature for 1 h. Ten thousand nuclei were analyzed for each sample, and CellFit software was used to quantify cell cycle compartments and estimate cell cycle phase fractions.
Western blot analysis
Cell pellets from control and IFN-α2b/PDF-treated cells were resuspended in cell lysis buffer and cell lysates were prepared by freeze-thaw three times in liquid nitrogen. The Western blot procedure essentially followed the protocol described previously . Briefly, an equal amount of proteins (7 μg) from control and IFN-α2b/PDF-treated cell lysates was resolved by 10% SDS-PAGE (SDS-polyacrylamide gel electrophoresis) and transferred to a nitrocellulose membrane. The blot was first incubated for 90 min with the primary antibodies against CDK2, CDK4, CDK6, cyclin D1, or cyclin E (Santa Cruz Biotechnology, Santa Cruz, CA), followed by incubation with the appropriate secondary antibody conjugates for 30 min. The specific immunoreactive proteins were then detected by chemiluminescence, following a vender's protocol (Kirkegaard and Perry Laboratories, Gaithersburg, MD), and quantified using a scan densitometer (Silk Scientific, Oregon, UT).
All data are presented as the mean ± SD (standard deviation), and statistical differences between groups were assessed with the unpaired Student's t test. A value of p < 0.05 is considered to be significant.
This study was supported by the Departmental Research Fund. We thank Mr. Mike Shirota (Maitake Products, Inc.) for kindly providing D-fraction (PDF).
- Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin. 1999, 49: 8-31. 10.3322/canjclin.49.1.8.View ArticlePubMedGoogle Scholar
- McLeod DG: Antiandrogenic drugs. Cancer. 1993, 71: 1046-1049. 10.1002/1097-0142(19930201)71:3+<1046::AID-CNCR2820711424>3.0.CO;2-M.View ArticlePubMedGoogle Scholar
- Davies P, Eaton CL: Regulation of prostate growth. J Endocrinol. 1991, 131: 5-17.View ArticlePubMedGoogle Scholar
- Hobeika AC, Etienne W, Cruz PE, Subramaniam PS, Johnson HM: IFNγ induction of p21waf1 in prostate cancer cells: Role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer. 1998, 77: 138-145. 10.1002/(SICI)1097-0215(19980703)77:1<138::AID-IJC21>3.0.CO;2-9.View ArticlePubMedGoogle Scholar
- Sica G, Iacopino F, Recchia F: Interferon and hormone sensitivity of endocrine-related tumors. Anticancer Drugs. 1996, 7: 150-160. 10.1097/00001813-199602000-00002.View ArticlePubMedGoogle Scholar
- Harris DT, Matyas GR, Gomella LG, Talor E, Winship MD, Spitler LE, Mastrangelo MJ: Immunologic approaches to the treatment of prostate cancer. Semin Oncol. 1999, 26: 439-447.PubMedGoogle Scholar
- Glashan RW: A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 1990, 144: 658-661.PubMedGoogle Scholar
- Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol. 2001, 19: 148-154.PubMedGoogle Scholar
- Van Haelst-Pisani CM, Richardson RL, Su J, Buckner JC, Hahn RG, Frytak S, Kvols LK, Burch PA: A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer. Cancer. 1992, 70: 2310-2312. 10.1002/1097-0142(19921101)70:9<2310::AID-CNCR2820700916>3.0.CO;2-4.View ArticlePubMedGoogle Scholar
- Mizuno T, Zhuang C: Maitake, Grifola frondosa: pharmacological effects. Food Rev Int. 1995, 11: 135-149.View ArticleGoogle Scholar
- Adachi K, Nanba H, Kuroda H: Potentiation of host-mediated antitumor activity in mice by β-glucan obtained from Grifola frondosa (maitake). Chem Pharm Bull (Tokyo). 1987, 35: 262-270.View ArticleGoogle Scholar
- Nanba H: Activity of Maitake D-fraction to inhibit carcinogenesis and metastasis. Ann NY Acad Sci. 1995, 768: 243-245. 10.1111/j.1749-6632.1995.tb12130.x.View ArticlePubMedGoogle Scholar
- Nanba H: Maitake D-fraction: Healing and preventive potential for cancer. J Orthomol Med. 1997, 12: 43-49.Google Scholar
- Reddy GP: Cell cycle: Regulatory events in G1-S transition of mammalian cells. J Cell Biochem. 1994, 54: 379-386. 10.1002/jcb.240540404.View ArticlePubMedGoogle Scholar
- Gutterman JU: Cytokine therapeutics: Lessons from interferon α. Proc Natl Acad Sci USA. 1994, 91: 1198-1205. 10.1073/pnas.91.4.1198.PubMed CentralView ArticlePubMedGoogle Scholar
- Gutterman JU, Blumenschein GR, Alexanian R, Yap HY, Buzdar AU, Cabanillas F, Hortobagyi GN, Hersh EM, Rasmussen SL, Harmon M, Kramer M, Pestka S: Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980, 93: 399-406.View ArticlePubMedGoogle Scholar
- Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z: Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982, 96: 549-556.View ArticlePubMedGoogle Scholar
- Rebouillat D, Hovanessian AG: The human 2',5'-oligoadenylate synthetase family: Interferon-induced proteins with unique enzymatic properties. J Interferon Cytokine Res. 1999, 19: 295-308. 10.1089/107999099313992.View ArticlePubMedGoogle Scholar
- Suhadolnik RJ, Sawada T, Gabriel J, Reichenbach NL, Henderson EE: Accumulation of low molecular weight DNA and changes in chromatin structure in HeLa cells treated with human fibroblast interferon. J Biol Chem. 1984, 259: 4764-4769.PubMedGoogle Scholar
- Konno-Sato S, Wu JM, Carter TH: Phosphorylation of a 72-kDa nucleoprotein (NP-72) in HL-60 cells is mediated by the double-stranded DNA-dependent protein kinase (DNA-PK). Biochem Mol Biol Int. 1993, 31: 113-124.PubMedGoogle Scholar
- Anderson CW, Lees-Miller SP: The nuclear serine/threonine protein kinase DNA-PK. Crit Rev Eukaryot Gene Expr. 1992, 2: 283-314.PubMedGoogle Scholar
- Kramer G, Steiner GE, Sokol P, Handisurya A, Klingler HC, Maier U, Foldy M, Marberger M: Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res. 2001, 21: 475-484. 10.1089/10799900152434349.View ArticlePubMedGoogle Scholar
- Maitake Products Inc: D-fraction obtained IND for clinical study. Corporate Publication. 1998Google Scholar
- Mordente JA, Konno S, Chen Y, Wu JM, Tazaki H, Mallouh C: The effects of brefeldin A (BFA) on cell cycle progression involving the modulation of the retinoblastoma protein (pRB) in PC-3 prostate cancer cells. J Urol. 1998, 159: 275-279. 10.1016/S0022-5347(01)64081-3.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.